We find out what were the challenges in this epic race against the virus and ask what remain the hurdles and opportunities for the global pharmaceutical industry.
An adjuvant developed with funding from the National Institutes of Health has contributed to the success of the highly efficacious COVAXIN COVID-19 vaccine, which roughly 25 million people have received to date in India and elsewhere. Adjuvants are substances formulated as part of a vaccine to boost immune responses and enhance a vaccine’s effectiveness. COVAXIN was developed and is manufactured in India, which is currently suffering a devastating health crisis due to COVID-19.
Craig Snyder, CEO of Indigo Global Corporation and Political and Corporate consultant, suggests the Biden Administration initiate a massive vaccine diplomacy initiative and purchase various vaccines including COVAXIN, to vaccinate majority of humanity across the globe to control the pandemic.
Data showing Covaxin-induced sera can neutralize B.1.617 as well as the B.1.128 variant first identified in Brazil has the stock up 24% to $15.68 for a valuation of $3.1 billion.
Ocugen announces studies showing COVAXIN potentially effective against three key variants of SARS-CoV-2
COVAXIN effectively neutralizes Brazil variant along with UK variant and India double mutant variant.
B.1.617 variant, which is effectively neutralized by COVAXIN, rapidly spreading in 17 countries including US
The ‘Indian strain’ of the coronavirus, which has triggered a second wave of COVID-19 cases in the country, has been detected in at least 17 countries, according to the World Health Organization (WHO).
COVAXIN found to neutralize the 617 variant of virus, says NIAID Director and Chief Medical Advisor to the President, Dr. Anthony Fauci
Covaxin, India's home-grown COVID-19 vaccine, has been found to neutralise the 617 variant of the deadly virus, White House chief medical adviser and America's top pandemic expert Dr Anthony Fauci said here.